The latest clinical evidence of Xianbisin® was unveiled at the 8th European Stroke Conference (ESOC)

“Whether treated with thrombolytic treatment or not, edaravone dexcampanol significantly reduced levels of inflammatory factors and improved neurological function in AIS patients.” From May 4 to 6, 2022, in a poster study published at the 8th European Stroke Conference (ESOC), clinical experts from China reached the above conclusions through retrospective clinical analysis.

This study, led by Qu Lixin's team, director of the Department of Neurology at Dezhou People's Hospital in Shandong Province compared the curative effects of four different treatment regimens on neurological function recovery and inflammation-related factors in patients with acute ischemic stroke (AIS).

Effects of edaravone dexcamol on neurological function and serum inflammatory factors in patients with acute ischemic stroke

The authors retrospectively analyzed the treatment status of nearly 200 patients with acute ischemic stroke admitted from September 2020 to April 2021. All selected patients had similar conditions before treatment, and were divided into 4 groups according to the treatment plan: 65 cases in the edaravone dexcamol group, 68 cases in the routine treatment group, 29 cases in the edaravone dexcamol plus ateplase thrombolysis group, and 35 cases in the alteplase thrombolysis group.

Changes in the NIHSS score, hs-CRP, TNF-α, and IL-6 levels of patients before and after treatment were statistically significant between the 4 groups. After the two were compared, the changes in NIHSS score, hs-CRP, TNF-α, and IL-6 in the edaravone dexcamol plus ateplase thrombolysis group decreased more than in the other 3 groups (P<0.05). The decrease in NIHSS score, hs-CRP, TNF-α, and IL-6 was higher than in the conventional treatment group (P<0.05) in patients in the edaravone dexcamol group and the ateplase thrombolysis group. The results suggest that regardless of whether thrombolytic treatment was received, Xianbixin® significantly reduced the level of inflammatory factors and improved neurological function in AIS patients, while the improvement in the combination treatment group with Xianbixin® and thrombolytic drugs was most obvious.

The study showed the international academic community the latest evidence on the efficacy of Xianbixin®, the only new stroke drug approved for marketing in the world since 2015, providing a further basis for clinical application of the drug.

Hosted by the European Stroke Organization, ESOC is one of the most important clinical academic conferences in Europe. Every year, it attracts thousands of professionals from more than 100 countries to exchange and share the latest academic progress in stroke around the world.

Xianbixin® is a new type of stroke drug independently developed by Xiansheng Pharmaceutical. It has appeared twice in a row at the ESOC conference with high-quality data in the two years since its launch, and is gradually gaining attention and recognition from the international clinical academic community.